Login / Signup

Short and Mid-Term Predictors of Response to OnabotulinumtoxinA: Real-Life Experience Observational Study.

Alicia AlpuenteVíctor José GallardoMarta Torres-FerrúsJosé Álvarez-SabinPatricia Pozo-Rosich
Published in: Headache (2020)
Patients with daily frequency and MO show a clinical improvement in short-term. Patients with comorbidities who start treatment earlier in the course of the disease need a longer duration of treatment. The profile of response to treatment with OnabotulinumtoxinA determines its minimum treatment duration and the timepoint of a meaningful response.
Keyphrases